EZH2 and central nervous system cancer: We found that the wild-type and IDH1R132H mouse glioma cells were equally insensitive to treatment after 72 h with EZH2 inhibitor Tazemetostat and did not reach IC50 even at 64 μM (Supplementary Figure S1E), although the treatment was effective in reducing H3K27me3 at doses as low as 0.03 μM (Supplementary Figure S1F).